Raymond James downgrades Ascendis Pharma stock rating on partnership shift
Investing.com
Raymond James downgraded Ascendis Pharma from Strong Buy to Outperform but maintained a $287 price target, following Ascendis Pharma's announcement that it will regain rights to TransCon metabolic and cardiovascular programs from Novo Nordisk and initiate a $400 million share repurchase. The firm notes that while this shift may prolong the timeline for significant upside, the company's fundamentals remain strong, particularly with its Yorvipath product. Other analysts, including H.C. Wainwright,
Read the full story
This is a short summary. The complete article is published by Investing.com.
Headline and summary aggregated from public news feeds. For information only — not financial advice.